Sector News

Daiichi axes 170-person Indian R&D site

January 11, 2017
Life sciences

Daiichi Sankyo is to shutter its 170-person Indian R&D site. The Japanese drugmaker brought the site into its network in 2010 following its $4.6 billion acquisition of Ranbaxy Laboratories, but has now decided it can boost R&D productivity by axing the operation.

Today, a team of 170 people work at the facility on the discovery and preclinical development of small molecules against infectious and autoimmune diseases. Under Ranbaxy the unit chalked up some successes, gaining a reputation for its synthetic chemical research capabilities and becoming the heart of an alliance with GlaxoSmithKline. But Daiichi management has decided to close the unit and transfer pipeline programs in development at the site to its main R&D division.

The decision is part of a broader effort at Daiichi to cut R&D costs and focus remaining resources on areas other than those worked on at the site in Gurgaon, India. That facility joins R&D sites in the United Kingdom and Germany on the list of those axed by Daiichi in the past two years.

In parallel to the internal cuts, Daiichi has penned a string of oncology deals designed to give it a pipeline of candidates that can increase its success rate in the clinic. The most recent and high profile of these agreements is the deal with Kite Pharma, which gave Daiichi the rights to CAR-T drug KTE-C19 in Japan. KTE-C19 is now spearheading an immuno-oncology pipeline that Daiichi is hoping to flesh out through collaborations with companies including AgonOx and Zymeworks.

The shift toward oncology and increased reliance on external collaborations rendered the Indian site a poor fit for the new look Daiichi. Gurgaon made more sense as a Daiichi outpost in 2010, when the Japanese drugmaker was in the middle of an ultimately doomed attempt to make India a cornerstone of its business. That strategy ended in 2014 when Daiichi cut its losses on its buyout of Ranbaxy.

By Nick Paul Taylor

Source: Fierce Biotech

comments closed

Related News

October 17, 2021

Colorcon acquires a majority share in Ideal Cures Pvt. Ltd., India

Life sciences

Ideal Cures will operate as a fully independent entity within Colorcon. Their business complements Colorcon’s position in the Indian pharmaceutical market with a strong presence in the domestic generic sector comprised of long-standing customer relationships sustained by innovative and customized solutions.

October 17, 2021

Barriers exist, but participation urgent in breast cancer clinical trials: report

Life sciences

Across four new breast cancer treatments approved by the FDA last year, 2% to 9% of patients in clinical trials for the drugs were Black Americans and 0% to 9% were Hispanic, according to a new report from Breastcancer.org.

October 17, 2021

Danish consortium acquires part of Jernbanebyen to create one of the world’s healthiest urban villages

Life sciences

The southern section of Jernbanebyen in central Copenhagen has a new owner. The Baneby Consortium, comprising NREP, Novo Holdings and Industriens Pension, has bought the land from Freja Ejendomme. The ambition is to create a green, partly car-free environment that will also be one of the healthiest in the world. 

Send this to a friend